



# OHSU SIREN NETWORK NEWS

Issue: October 2021

## CALENDAR

10/5 1 pm ET Study

Coordinator Meeting – [Zoom Link \(Meeting ID: 931 9105 3000 Passcode: 175158\)](#)

10/14 3-4pm ET Finance Committee Call – [Web Link](#)

10/20 1pm Journal Club – articles TBA -[Web Link](#)

10/27 12-1:30pm ET Steering Committee Meeting – [Zoom Link \( Meeting ID: 933 6447 5099 Passcode: 521223\)](#)

11/2 1pm ET Study Coordinator Meeting [Zoom Link](#); Meeting ID: 919 3380 5008 Passcode: 172195

Contact us: Jenny Cook, Coordinator, 503.494.1230 [cookjen@ohsu.edu](mailto:cookjen@ohsu.edu) [OHSU SIREN Website](#) Twitter: [@OHSU CPREM](#)

## Newsletter at a Glance

- OHSU Network SIREN Renewal Grant ..... 1
- OHSU Network SIREN Investigator Meeting ..... 1
- Network News & Updates ..... 2
- BOOST 3 News & Updates ..... 2
- ICECAP News & Updates ..... 2
- HOBIT News & Updates ..... 3
- C3PO News & Updates ..... 3
- CTMC Series updates ..... 3
- Glossary of Frequently Used Abbreviations ..... 3

## OHSU NETWORK SIREN RENEWAL GRANT

No news yet, and no updates to the anticipated release of the FOA.

## OHSU NETWORK SIREN INVESTIGATOR MEETING


Thank you to those sites who were able to attend! Here are a few highlights from our discussions.

1. Recent data lock for upcoming DSMB meeting. Please use this as a reminder to stay current on your Case Report Forms (CRF’s) for all studies. Each trial has a schedule and deadlines for the timeliness of CRF submission into WebDCU – please make sure you are familiar with the schedule, and entering your data in a timely manner.
2. Potential trial ideas- Dr. Wang (OSU), and Dr. Youngquist (Utah) have a pre-hospital EMS based IM epi trial they are working on developing now. Dr. Khan (URMC), has been working on an ECPR-

ECMO trial idea. If you and your team have a trial idea that might be included in the SIREN renewal grant, please contact Jenny Cook ([cookjen@ohsu.edu](mailto:cookjen@ohsu.edu)) to set up a meeting time with Drs. Daya and Kea to discuss inclusion in the application. Each HUB submitted 2 potential trial ideas in the first funding cycle.

3. Site study updates:
  - a. Duke & OSU have both experienced challenges with the HOBIT trial and currently have this trial on hold at their sites while they work through these issues.
  - b. URMC & OHSU noted some equipment issues in relation to the BOOST 3 study. Both sites are working to resolve these, but are not currently on hold.
  - c. ICECAP – group discussion around issues with cooling to under 34C in 4 hours were discussed, and best practices that have been effective site by site, such as external cooling with patient belonging bags filled with ice.

## NETWORK NEWS & UPDATES



- Total OHSU Network enrollment: 190
  - Despite the challenges discussed, the OHSU network continues to be the top performing network, and most sites continue to be top enrollers in all trials they are participating in. This is truly an amazing dream team!
  - There are currently 167 outstanding CRF's (98.4% completion rate). This represents an enormous amount of effort by our sites to stay caught up. Can you get completion rate to 100%?

## BOOST 3 NEWS & UPDATES

- BOOST 3 enrollments: 237 (Target enrollment 1094)
- **OHSU Network Enrollment: 60**
- Bio-BOOST enrollments: 17 ; **OHSU Network: 8.**
- The executive team is working on protocol updates to add clarity and address some items that have been discovered since trial initiation. Stay tuned.
- Electro-BOOST is still in the process of starting up. More info on the website: <https://siren.network/clinical-trials/boost-3/electro-boost>

## ICECAP NEWS & UPDATES

- Enrollment: 301 (Goal: 1800)
- **OHSU Network Enrollment: 52**
- Reminder to keep your screening logs current. This data is very important and required by the FDA!

## HOBIT NEWS & UPDATES

- Enrollment: 66 (Goal:200)
- **OHSU Network enrollment: 9**
- Reminder to keep screening logs current. These logs are helping trial leadership understand the challenges and barriers that are impacting this study.

## C3PO NEWS & UPDATES

- Have an idea for a secondary research paper? Submit your C3PO ideas here: Please note that additional data related to inflammatory markers including anti-spike antibody levels as well as other tests will be available soon.
- If you would like to join a writing group for a trial idea already on the website. Contact the lead author to request to be added to the team.

## CTMC SERIES UPDATES

The CTMC Fall 2021 schedule has changed. The below webinars have been cancelled or rescheduled. Carefully review the below schedule for updates. As a reminder, the full schedule and all previous webinar recordings can be accessed [here](#).

Webinar	Update
<b>October 18: NINDS Health Disparities &amp; Global Health Agenda / Common Data Elements</b>	<b>CANCELLED</b>
<b>October 25: From Statistical Significance to Clinical Significance: Time to Dethrone or get rid of Significance?</b>	<b>CANCELLED</b>
<b>November 8: What comes next?</b>	<b>Rescheduled to 11/15 at 12:00 – 1:00pm</b>
<b>November 22: What will the CTMC look like in 2022?</b>	<b>CANCELLED (Content incorporated into 11/15 webinar)</b>

## GLOSSARY OF FREQUENTLY USED ABBREVIATIONS

CCC = Central Coordinating Center (i.e. University of Michigan)  
EFIC= Exception from informed consent  
CC = Community Consultation  
PD = Public Disclosure  
cIRB = Central IRB (in this case Advarra)